Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email:  
Bone and Cancer

Clinical Trials

Mavik (trandolapril)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved May 1996

Specific Treatments:


General Information

Mavik is an angiotensin converting enzyme (ACE) inhibitor indicated for the treatment of hypertension when used alone or in combination with other antihypertensive medication, such as hydrochlorothiazide. Knoll Pharmaceutical Company expects to make Mavik available by prescription in one mg, two mg, and four mg dosage strengths. In Afro-American subjects, the minimal effective daily dose is two mg (versus one mg in Caucasians).

Clinical Results

In clinical studies, Mavik was shown to provide excellent 24-hour blood pressure control when taken once daily.

Side Effects

Mavik was well tolerated in clinical trials. The most common side effects were cough (1.9%), dizziness (1.3%), and diarrhea (1.0%). Headache and fatigue occurred in less than 1% of patients, but were reported more often on placebo. Mavik is contraindicated in subjects who are hypersensitive to the product. Angiodema has been reported in subjects receiving ACE inhibitors.

Additional Information

The clinical significance of tissue ACE inhibition has not been established.

 How To Order Publications:

Information About

Clinical Trials



















  Copyright 2011 - The Bone and Cancer Foundation